Outcomes research

VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022

Retrieved on: 
Thursday, May 19, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Disease, HBV, VLP, Infection, Cirrhosis, Liver cancer, Allergy, Virus, VBI, Poster, Private Securities Litigation Reform Act, Headache, Immune system, SEC, Fatigue, Annual report, Anaphylaxis, Pharmacoeconomics, CMV, International Society, Pain, Woman, Outcomes research, Nature, European, COVID-19, Research, Immunodeficiency, GBM, Company, Hepatitis B, Health Economics, Myalgia, New Resource Bank, International Society for Pharmacoeconomics and Outcomes Research, VAERS, Hepatocellular carcinoma, Pregnancy, Hepatitis B virus, Tenderness, History, Nasdaq, Patient, EU, Cytomegalovirus, Vaccine, Industry, Liver disease, Glioblastoma, Person, News, Medicine, Birth control

Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.

Key Points: 
  • Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.
  • An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

New Research Finds Computer Assisted Colonoscopy Identify More Precancerous Polyps Compared to Traditional Colonoscopy

Retrieved on: 
Tuesday, May 24, 2022
Cancer, Physician, Colon, MBA, Polyp, Use, Death, AI, Incidence, Doctor of Philosophy, Adenoma, Patient, Colonoscopy, Colorectal cancer, MMSc, Outcomes research, NYU, MPH, Mortality, Artificial intelligence, Large intestine, BS, Research, Hepatology, Literature, Histology, Conference, MS, Division, Pathology, Polyp (medicine), Trial of the century, New York University Grossman School of Medicine, Growth, Diagnosis, Rectum, Medical device, Medical imaging, Medicine, Gastroenterology, MD

Colonoscopy is considered the most effective test for colorectal cancer screenings and prevention as the procedure reduces the incidence and mortality through early detection.

Key Points: 
  • Colonoscopy is considered the most effective test for colorectal cancer screenings and prevention as the procedure reduces the incidence and mortality through early detection.
  • During a colonoscopy, a doctor inserts and threads a narrow, flexible tube called a colonoscope into the rectum and through the entire colon, or large intestine.
  • A computer-aided detection was developed for the identification of colorectal polyps during high-definition white-light colonoscopy procedures.
  • The number of polyps found using a computer-aided colonoscope was 1.05 compared to .82 and there was no decrease in the true histology rate indicating the polyps of concern were all removed.

OSF HealthCare collaborates to test blockchain-based app to reward healthy behaviors

Retrieved on: 
Tuesday, May 10, 2022
Champaign County, Illinois, Innovation, Nursing, Privacy, Museum, Data, Grainger College of Engineering, Business, Outcomes research, University, Student, Health, Third order, Bed, UIUC, Research, Blockchain, Physician, College, ARCHES, German Cancer Research Center, Faculty, Gies College of Business, Sister, Diagnosis, Hospital, University of Cincinnati College of Engineering and Applied Science, Virtual reality, Behavior, University of Illinois Urbana-Champaign, Immersion, Center, OSF, University of Illinois College of Medicine, Education, Applied science, Solution, College of Medicine (UK), Partner (business rank), Technology, Community health, OSF HealthCare, Multimedia, Illinois College, Management, Cryptocurrency, Video game console, Online shopping, Pharmaceutical industry, Medicine, Jump, Engineering

Ralph says consumers using the blockchain-based rewards app could be rewarded quickly for exercising, taking medication, or any number of other healthy behaviors, unlike the kinds of programs insurance companies currently offer clients.

Key Points: 
  • Ralph says consumers using the blockchain-based rewards app could be rewarded quickly for exercising, taking medication, or any number of other healthy behaviors, unlike the kinds of programs insurance companies currently offer clients.
  • Other systems (insurance reward programs), will take a lot longer and it'll be harder to see directly the impact of what you're doing."
  • OSF HealthCare, through OSF Home Care Services, operates an extensive network of home health and hospice services.
  • Jump Trading Simulation and Education Center, a part of OSF Innovation , is a collaboration between University of Illinois College of Medicine at Peoria and OSF HealthCare.

Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS

Retrieved on: 
Tuesday, April 19, 2022
Health, FDA, Infectious Diseases, General Health, Research, Science, Pharmaceutical, CRP, National Health Service, ClinicoEconomics and Outcomes Research, National Health Service (England), Nasdaq, United Kingdom, SOC, Patient, COVID-19, Outcomes research, Pharmaceutical industry

The publication demonstrated, in all cases, lenzilumab plus SOC improved all specified clinical outcomes compared with SOC alone.

Key Points: 
  • The publication demonstrated, in all cases, lenzilumab plus SOC improved all specified clinical outcomes compared with SOC alone.
  • Additionally, patient selection, utilizing CRP
  • The observed cost savings are mainly driven by fewer bed days, days on invasive mechanical ventilation and ICU days.
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.

Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session

Retrieved on: 
Sunday, April 3, 2022
Hospital, Kidney, Exercise, Risk, Heart failure, University, HF, CV, Heart, Yale School of Medicine, NYHA, Death, Health, Blood, University of Glasgow, Digoxin, RRR, NNT, Patient, Evaluation, MPH, Standard of care, Associate, New York Heart Association Functional Classification, Cardiology, ARR, Center, Systole, Outcomes research, Duke University School of Medicine, American College, Institute, GLOBE, Cytokinetics, Medicine, LVEF, NDA, EF, Contractility, Prescription Drug User Fee Act, Atrial fibrillation, PDUFA, CPET, SAN, Research and development, FDA, Prognosis, Functional, Pharmaceutical industry, Medical device

SOUTH SAN FRANCISCO, Calif., April 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results from METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), a Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), were presented by Michael Felker, M.D., Professor of Medicine, Duke Clinical Research Institute, at the American College of Cardiology 71st Annual Scientific Session (ACC.22). Additional data from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) were also presented including a healthcare resource utilization analysis and an analysis of the effect of treatment with omecamtiv mecarbil in hospitalized patients compared to outpatients.

Key Points: 
  • After 20 weeks of treatment, there was no change in pVO2 in patients treated with omecamtiv mecarbil versus placebo.
  • Adverse events, including major cardiac events, were similar between the treatment arms, even with patients reaching peak exercise.
  • For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Accountable Care Organizations are Early Adopters of Innovative Care Profiles

Retrieved on: 
Tuesday, March 29, 2022
Hospital, Risk, Organization, Benchmarking, Population, Partnership, Falls, Physician, Accountable care organization, BCDA, ACO, Research, CMS, HEALTH, CEO, CHF, Infection, Outcomes research, Sone, Disease management, Department, Acos, Patient, Health insurance, Risk management, Medicine

BOSTON, March 29, 2022 /PRNewswire/ -- Over the last several months, a growing number of Accountable Care Organizations (ACOs) are adding predictive analytics to the systems they use to manage care through a partnership program sponsored by Health Data Analytics Institute (HDAI).

Key Points: 
  • "Our goal is to leverage our predictive analytic platform to synthesize existing data and deliver insightful care profiles.
  • This facilitates the diagnostic process for clinicians and enables more targeted and personalized care for patients.
  • By partnering with these forward-thinking ACOs, we are advancing their mission to deliver value-based care and better outcomes."
  • HDAI delivers web-based, secure, patient-level care profiles, using the Beneficiary Claims Data API (BCDA) authorized by CMS, allowing live deployment in as little as 48 hours.

Asher Bio Expands Leadership Team with Three Key Appointments

Retrieved on: 
Monday, January 24, 2022
Biotechnology, Pharmaceutical, Health, Third Rock Ventures, Doctor of Philosophy, New Paltz, New York, Research, Patient, Regulatory affairs, Guidant, University, LinkedIn, Codexis, Biotechnology, Tufts University, Forty-seven rōnin, Regulation of tobacco by the U.S. Food and Drug Administration, Market for corporate control, Molecular biology, Wharton School of the University of Pennsylvania, Gilead Sciences, Autoimmunity, Amgen, Leadership, Infection, CPA, Industry, Varian, Inc., Program, Therapy, Davis, 5, University of Washington Department of Global Health, Certified Public Accountant, Toxicity, Cancer, Food, State university system, Outcomes research, FDA, LLC, Wendell Pritchett, Imperial College London, Head, Pharmaceutical industry, Vaccine, Genentech, Biology, Biochemistry, Immunology

We are delighted to welcome Don, Jamie and Florence to Asher Bio, said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.

Key Points: 
  • We are delighted to welcome Don, Jamie and Florence to Asher Bio, said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.
  • Dr. OSullivan joins Asher Bio from Roche and Genentech, where he served most recently as Vice President, Global Head of Oncology Partnering, with responsibility for all oncology pipeline business development activities.
  • Prior to Asher Bio, Dr. Cross founded and served as the principal regulatory consultant of Cross BioStrategies, LLC, where he assisted companies with product development strategies, regulatory filings, and regulatory leadership.
  • Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco.

Latest Jump ARCHES awards focus on medical tech solutions to address vexing health care challenges

Retrieved on: 
Thursday, January 20, 2022
Medicine, Champaign County, Illinois, Research, OSF HealthCare, Data, Partner (business rank), Museum, University of Illinois Urbana-Champaign, College of Medicine (UK), Physician, Athlete, Concussion, Outcomes research, University of Illinois College of Medicine, Technology, COVID-19, Social, Third order, Digital health, Student, Kansas State University College of Engineering, Psychiatry Innovation Lab, Multimedia, Applied science, Hospital, Intubation, Grainger College of Engineering, Partnership, Health literacy, News, Sister, Solution, Health, Center, Child, Education, Illinois College, Behavioural sciences, College, German Cancer Research Center, Nursing, FAAP, CSBS, Migraine, Engineering, IOT, Poverty, Bed, OSF, View, Community health, Faculty, University, Virtual reality, ARCHES, Pharmaceutical industry, Jump, MD

The funding supports research involving clinicians, engineers, and social scientists to rapidly develop technologies and devices that could revolutionize medical training and health care delivery.

Key Points: 
  • The funding supports research involving clinicians, engineers, and social scientists to rapidly develop technologies and devices that could revolutionize medical training and health care delivery.
  • He adds, "We know digitally connected health systems, powerful data analytics, and new innovative approaches offer the promise of universal standard care and health knowledge for everyone we serve."
  • HCESC designs collaborative solutions to improve health care outcomes utilizing their expertise in simulation technologies, smart health systems, data analytics, human factors and medical robotics.
  • HCESC partners with Jump in this innovative relationship of Applied Research for Community Health through Engineering and Simulation (ARCHES).

Intravascular ultrasound (IVUS) linked with improved health outcomes in largest-ever real-world analysis of lower extremity peripheral vascular interventions

Retrieved on: 
Monday, November 8, 2021
Health, Mortality, TCT, Amputation, Stenosis, Outcomes research, Centers for Medicare & Medicaid Services, CMS, Medicare, Moyamoya disease, MD, PAD, Chronic limb threatening ischemia, Boston Scientific, Ageing, Technology, Philips, Harvard Medical School, Peripheral artery disease, Senior, Beth Israel Deaconess Medical Center, USA, Interventional cardiology, Software, Fatigue, Decision-making, Plaque, IVUS, Leg, Cohort study, Research, Smith Center, PHG, Solution, CLI, Hospital, Foot, Center, NYSE, Death, CVD, Physician, Review, Assistant, Vascular disease, Patient, VIVA, Risk, Literature, AEX, Meat, Birth control, Pharmaceutical industry, Medical imaging

Numerous prospective studies have already shown the benefit of IVUS guidance in peripheral vascular interventions, making it a gold-standard imaging modality for this application.

Key Points: 
  • Numerous prospective studies have already shown the benefit of IVUS guidance in peripheral vascular interventions, making it a gold-standard imaging modality for this application.
  • The results of this large-scale study demonstrate favorable long-term outcomes in peripheral vascular interventions when IVUS is used, said Eric Secemsky, MD.
  • Peripheral artery disease (PAD): a 32% reduction in major adverse limb events, including amputations, during lower extremity arterial interventions
    The study looked at Medicare beneficiaries aged 65 years or older who underwent lower extremity arterial interventions between January 1, 2016, and December 31, 2019.
  • Peripheral artery disease develops when plaque builds up in the vessel wall and reduces blood flow to the limbs, most commonly the legs.

Pear Therapeutics Announces Publication Showing Cost Savings and Decreased Hospital Encounters for Opioid Use Disorder Patients Treated with reSET-O® Compared to Control Patients During Nine-Month Period Following Prescription

Retrieved on: 
Wednesday, November 3, 2021
Technology, Biotechnology, FDA, Health, Pharmaceutical, Mental Health, Physical Therapy, Medical Devices, Software, Infectious Diseases, General Health, Hardware, Data Management, Clinical Trials, Digital, Suicidal ideation, Insomnia, BA, Treatment, Language isolate, Clinical study design, Substance Abuse and Mental Health Services Administration, Industry, Opioid use disorder, Naloxone, Buprenorphine, PDT, MBA, Journal of Medical Economics, SUD, OUD, Current Medical Research and Opinion, PMID, Patient, FDA, Risk, Postgraduate Medicine, Cognitive behavioral therapy, ICU, Pear, Smartphone, JAMA Internal Medicine, Outcomes research, Policy by press release, Food and Drug Administration, Social isolation, Pharmacoeconomics, DOI, Safety, Policy, Health, Mental health service, Death, Therapy, National Survey on Drug Use and Health, Population, Doctor of Philosophy, Incidence, Journal, Reading, Veni, vidi, vici, National, Pharmaceutical industry, Health insurance, Medical device

In the study, HCRU was measured during the nine-month period following a patients first prescription of reSET-O.

Key Points: 
  • In the study, HCRU was measured during the nine-month period following a patients first prescription of reSET-O.
  • The resulting net cost savings over the 9-month period of $2,708 per treated patient was largely driven by a 46% lower incidence of hospital-related stays.
  • The results of this analysis showed that patients who were treated with reSET-O showed substantially lower incidence of hospital encounters, particularly inpatient stays and ICU stays, compared to control patients.
  • Total cost of hospital facility encounters was lower for treated patients versus control patients ($2,693 versus $6,130, respectively), while total per-patient cost for clinical services was $6,040 for treated patients versus $5,311 for control patients.